-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Valopicitabine dihydrochloride
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/640725-71-9.gif)
| Category | HCV Protease |
| CAS | 640725-71-9 |
| Description | Valopicitabine dihydrochloride is a nucleoside analogue and the orally bioavailable 2'-C-methylcytidine (NM107) prodrug, with anti-hepatitis C virus (HCV) activity. |
Product Information
| Synonyms | NM283 dihydrochloride; (2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-yl L-valinate dihydrochloride; 2'-C-Methyl-3'-O-L-valylcytidine dihydrochloride; Cytidine, 3'-O-[(2S)-2-amino-3-methyl-1-oxobutyl]-2'-C-methyl-, hydrochloride (1:2) |
| IUPAC Name | [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate;dihydrochloride |
| Molecular Weight | 429.30 |
| Molecular Formula | C15H26Cl2N4O6 |
| Canonical SMILES | CC(C)C(C(=O)OC1C(OC(C1(C)O)N2C=CC(=NC2=O)N)CO)N.Cl.Cl |
| InChI | InChI=1S/C15H24N4O6.2ClH/c1-7(2)10(17)12(21)25-11-8(6-20)24-13(15(11,3)23)19-5-4-9(16)18-14(19)22;;/h4-5,7-8,10-11,13,20,23H,6,17H2,1-3H3,(H2,16,18,22);2*1H/t8-,10+,11-,13-,15-;;/m1../s1 |
| InChIKey | XENHXZMAOSTXGD-DSMKLBDQSA-N |
| Purity | ≥98% |
| Solubility | Soluble in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Store at -20°C, protect from light, stored under nitrogen |
| Complexity | 607 |
| Exact Mass | 428.1229399 |
| In Vivo | Valopicitabine (NM 283) has potent antiviral activity against chronic hepatitis C virus genotype-1 in the chimpanzee. Valopicitabine exhibits moderate Cmax (3.62 ug/mL) and terminal elimination half-lives (T1/2 0.64 h) following oral administration (100 mg/kg) in Sprague-Dawley rats. |
| PSA | 163.91000 |
| Target | HCV; HCV Protease; Nucleoside Antimetabolite/Analog |
